|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
|
US7569551B2
(en)
|
2000-02-25 |
2009-08-04 |
The University Of British Columbia |
Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
|
|
UA73993C2
(uk)
*
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
|
DE10031971A1
(de)
*
|
2000-06-30 |
2002-01-10 |
Goedecke Ag |
Polymorphe Formen/Hydrate von N-[4-(3-Chlor-4-fluor-phenylamino)-7-(3-morpholin-4-yl-propoxy)-chinazolin-6-yl]-acrylamid Dihydrochlorid, Verfahren zu ihrer Herstellung sowie die Verwendung derselben zur Herstellung von Medikamenten mit irreversibler Tyrosinkinasehemmwirkung
|
|
EP1170011A1
(en)
*
|
2000-07-06 |
2002-01-09 |
Boehringer Ingelheim International GmbH |
Novel use of inhibitors of the epidermal growth factor receptor
|
|
AU2001295002B2
(en)
*
|
2000-08-09 |
2007-05-31 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
|
US6403580B1
(en)
|
2000-08-26 |
2002-06-11 |
Boehringer Ingelheim Pharma Kg |
Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
DE10042064A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
US20020119148A1
(en)
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
|
EP1506962B1
(en)
|
2000-10-20 |
2008-07-02 |
Eisai R&D Management Co., Ltd. |
Nitrogen-containing aromatic heterocycles
|
|
US7776315B2
(en)
|
2000-10-31 |
2010-08-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and additional active ingredients
|
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
|
NZ516873A
(en)
*
|
2001-02-12 |
2003-11-28 |
Warner Lambert Co |
Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
|
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
|
KR101166214B1
(ko)
|
2002-01-17 |
2012-07-16 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법
|
|
DE10221018A1
(de)
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
|
WO2003101491A1
(en)
*
|
2002-06-03 |
2003-12-11 |
Mitsubishi Pharma Corporation |
PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
|
|
JP4703183B2
(ja)
|
2002-07-15 |
2011-06-15 |
シンフォニー エボルーション， インク． |
受容体型キナーゼモジュレーターおよびその使用方法
|
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
|
US7687506B2
(en)
|
2003-04-11 |
2010-03-30 |
The Regents Of The University Of California |
Selective serine/threonine kinase inhibitors
|
|
KR101126560B1
(ko)
|
2003-05-30 |
2012-04-05 |
도꾜 다이가꾸 |
약제 반응 예측 방법
|
|
EP2389953A1
(en)
|
2003-06-09 |
2011-11-30 |
Samuel Waksal |
Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
|
|
NZ545459A
(en)
|
2003-08-14 |
2009-12-24 |
Array Biopharma Inc |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
|
US7501427B2
(en)
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
|
GB0321066D0
(en)
*
|
2003-09-09 |
2003-10-08 |
Pharma Mar Sau |
New antitumoral compounds
|
|
GB0321620D0
(en)
*
|
2003-09-16 |
2003-10-15 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US7569577B2
(en)
*
|
2003-09-16 |
2009-08-04 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
|
ES2651730T3
(es)
*
|
2003-09-26 |
2018-01-29 |
Exelixis, Inc. |
Moduladores c-Met y métodos de uso
|
|
JP4303726B2
(ja)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
|
RU2402569C2
(ru)
|
2004-03-19 |
2010-10-27 |
Имклоун Элэлси |
Человеческие антитела к рецептору эпидермального фактора роста
|
|
CA2561516A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
US8080577B2
(en)
|
2004-05-06 |
2011-12-20 |
Bioresponse, L.L.C. |
Diindolylmethane formulations for the treatment of leiomyomas
|
|
RS52119B
(sr)
*
|
2004-05-06 |
2012-08-31 |
Warner-Lambert Company Llc |
4-fenilamino-hinazolin-6-il-amidi
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
US8969379B2
(en)
|
2004-09-17 |
2015-03-03 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
WO2006071079A1
(en)
*
|
2004-12-29 |
2006-07-06 |
Hanmi Pharm. Co., Ltd. |
Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
|
|
EP1838303B1
(en)
|
2004-12-30 |
2011-02-09 |
Bioresponse LLC |
Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
|
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
|
CN101612399B
(zh)
|
2005-06-17 |
2013-11-27 |
英克隆有限责任公司 |
用作治疗继发性骨肿瘤的抗PDGFRα抗体
|
|
WO2007015578A1
(ja)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を検定する方法
|
|
JP2009505658A
(ja)
|
2005-08-24 |
2009-02-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
|
|
KR100832593B1
(ko)
*
|
2005-11-08 |
2008-05-27 |
한미약품 주식회사 |
신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법
|
|
EP3173084B1
(en)
|
2005-11-11 |
2019-10-23 |
Boehringer Ingelheim International GmbH |
Quinazoline derivatives for the treatment of cancer diseases
|
|
DE602006009968D1
(de)
|
2005-11-15 |
2009-12-03 |
Array Biopharma Inc |
N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
|
|
CA2652442C
(en)
|
2006-05-18 |
2014-12-09 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
|
EP2065372B1
(en)
|
2006-08-28 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
|
ES2372217T3
(es)
|
2006-09-12 |
2012-01-17 |
Genentech, Inc. |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
|
|
SI2068880T1
(sl)
|
2006-09-18 |
2012-08-31 |
Boehringer Ingelheim Int |
Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
|
|
BRPI0717753B1
(pt)
|
2006-10-27 |
2022-04-12 |
Bioresponse, Llc |
Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição
|
|
US8962655B2
(en)
|
2007-01-29 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
|
EP2207561A2
(en)
*
|
2007-10-19 |
2010-07-21 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
|
CN101848895B
(zh)
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
血管新生抑制物质和抗肿瘤性铂络合物的组合使用
|
|
WO2009067543A2
(en)
*
|
2007-11-19 |
2009-05-28 |
The Regents Of The University Of Colorado |
Treatment of histone deacetylase mediated disorders
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
WO2009095480A1
(en)
*
|
2008-01-30 |
2009-08-06 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
|
CN101965192A
(zh)
*
|
2008-03-07 |
2011-02-02 |
法马马有限公司 |
改善的抗肿瘤治疗
|
|
CN101544609A
(zh)
|
2008-03-25 |
2009-09-30 |
上海艾力斯医药科技有限公司 |
4-苯胺喹唑啉衍生物的结晶形式
|
|
CA2758030C
(en)
|
2009-01-16 |
2019-01-08 |
Exelixis, Inc. |
Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
|
AR075896A1
(es)
|
2009-03-20 |
2011-05-04 |
Genentech Inc |
Anticuerpos anti-her (factor de crecimiento epidermico)
|
|
US8530492B2
(en)
|
2009-04-17 |
2013-09-10 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
|
HRP20191005T1
(hr)
|
2009-07-06 |
2019-08-23 |
Boehringer Ingelheim International Gmbh |
Postupak sušenja bibw2992, njegovih soli i čvrstih farmaceutskih formulacija koje sadrže taj djelatni sastojak
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
NZ620174A
(en)
|
2009-09-16 |
2016-08-26 |
Celgene Avilomics Res Inc |
Protein kinase conjugates and inhibitors
|
|
EP2494070A2
(en)
|
2009-10-30 |
2012-09-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
|
CA2780319A1
(en)
|
2009-11-12 |
2011-05-19 |
Genentech, Inc. |
A method of promoting dendritic spine density
|
|
EP2519664A4
(en)
|
2009-12-30 |
2014-03-12 |
Avila Therapeutics Inc |
LIGAND-RELATED COVALENTS MODIFYING A PROTEIN
|
|
KR20140015162A
(ko)
|
2010-01-12 |
2014-02-06 |
에프. 호프만-라 로슈 아게 |
트라이사이클릭 헤테로사이클릭 화합물, 조성물 및 이의 사용 방법
|
|
SG183333A1
(en)
|
2010-02-18 |
2012-09-27 |
Genentech Inc |
Neuregulin antagonists and use thereof in treating cancer
|
|
JP2013522267A
(ja)
|
2010-03-17 |
2013-06-13 |
エフ．ホフマン−ラ ロシュ アーゲー |
イミダゾピリジン化合物、組成物、および使用法
|
|
KR20130058672A
(ko)
|
2010-04-16 |
2013-06-04 |
제넨테크, 인크. |
ＰＩ3Ｋ/ＡＫＴ 키나제 경로 억제제 효능에 대한 예측 바이오마커로서의 ＦＯＸＯ３ａ
|
|
ES2573515T3
(es)
|
2010-06-25 |
2016-06-08 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
|
|
JP2013537966A
(ja)
|
2010-08-31 |
2013-10-07 |
ジェネンテック， インコーポレイテッド |
バイオマーカー及び治療の方法
|
|
CN103209695A
(zh)
|
2010-09-15 |
2013-07-17 |
弗·哈夫曼-拉罗切有限公司 |
氮杂苯并噻唑化合物、组合物及应用方法
|
|
JP2013542966A
(ja)
|
2010-11-19 |
2013-11-28 |
エフ．ホフマン−ラ ロシュ アーゲー |
ピラゾロピリジンならびにｔｙｋ２阻害剤としてのピラゾロピリジン及びそれらの使用
|
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
|
MX2013009931A
(es)
|
2011-04-18 |
2013-10-01 |
Eisai R&D Man Co Ltd |
Agentes terapeuticos contra tumores.
|
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
|
EP2714937B1
(en)
|
2011-06-03 |
2018-11-14 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
|
HK1199255A1
(en)
|
2011-08-12 |
2015-06-26 |
F. Hoffmann-La Roche Ag |
Indazole compounds, compositions and methods of use
|
|
CA2842375A1
(en)
|
2011-08-17 |
2013-02-21 |
Erica Jackson |
Neuregulin antibodies and uses thereof
|
|
WO2013041539A1
(en)
|
2011-09-20 |
2013-03-28 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
|
WO2013056069A1
(en)
|
2011-10-13 |
2013-04-18 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
|
EP2785864A2
(en)
|
2011-11-30 |
2014-10-08 |
F. Hoffmann-La Roche AG |
Erbb3 mutations in cancer
|
|
CA2865082A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
CN110507654A
(zh)
|
2012-04-03 |
2019-11-29 |
诺华有限公司 |
有酪氨酸激酶抑制剂的组合产品和其应用
|
|
MX2015004979A
(es)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Forma amorfa de derivado de quinolina y metodo para su produccion.
|
|
WO2014128235A1
(en)
|
2013-02-22 |
2014-08-28 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer and preventing drug resistance
|
|
HK1213180A1
(zh)
|
2013-03-06 |
2016-06-30 |
豪夫迈‧罗氏有限公司 |
治疗和预防癌症药物抗性的方法
|
|
US10035801B2
(en)
|
2013-03-13 |
2018-07-31 |
Genentech, Inc. |
Pyrazolo compounds and uses thereof
|
|
HK1220916A1
(zh)
|
2013-03-14 |
2017-05-19 |
基因泰克公司 |
治疗癌症和预防癌症药物抗性的方法
|
|
JP2016515132A
(ja)
|
2013-03-14 |
2016-05-26 |
ジェネンテック， インコーポレイテッド |
Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
|
|
RU2015143437A
(ru)
|
2013-03-15 |
2017-04-27 |
Дженентек, Инк. |
Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
|
|
NZ714049A
(en)
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
CN103242244B
(zh)
*
|
2013-05-16 |
2015-03-25 |
苏州明锐医药科技有限公司 |
一种卡奈替尼的制备方法
|
|
CA2922925A1
(en)
|
2013-09-05 |
2015-03-12 |
Genentech, Inc. |
Antiproliferative compounds
|
|
CN104513229A
(zh)
*
|
2013-09-28 |
2015-04-15 |
正大天晴药业集团股份有限公司 |
喹唑啉衍生物及其制备方法
|
|
AR097894A1
(es)
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
Inhibidores terapéuticos de cdk8 o uso de los mismos
|
|
WO2015058132A2
(en)
|
2013-10-18 |
2015-04-23 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
|
FI3083686T4
(fi)
|
2013-12-17 |
2023-05-09 |
|
Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja
|
|
BR112016013963A2
(pt)
|
2013-12-17 |
2017-10-10 |
Genentech Inc |
terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
|
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
|
CN107002119A
(zh)
|
2014-03-24 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
|
|
PE20161571A1
(es)
|
2014-03-31 |
2017-02-07 |
Genentech Inc |
Anticuerpos anti-ox40 y metodos de uso
|
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック， インコーポレイテッド |
抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
|
|
CN113683564A
(zh)
|
2014-08-28 |
2021-11-23 |
卫材R&D管理有限公司 |
高纯度喹啉衍生物及其生产方法
|
|
CN107074823B
(zh)
|
2014-09-05 |
2021-05-04 |
基因泰克公司 |
治疗性化合物及其用途
|
|
CN107073125A
(zh)
|
2014-09-19 |
2017-08-18 |
基因泰克公司 |
Cbp/ep300和bet抑制剂用于治疗癌症的用途
|
|
EP3204379B1
(en)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
|
JP2017536347A
(ja)
|
2014-10-17 |
2017-12-07 |
ノバルティス アーゲー |
セリチニブとｅｇｆｒ阻害剤の組合せ
|
|
CA2966523A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
SG11201703521UA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
EP3218376B1
(en)
|
2014-11-10 |
2019-12-25 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
|
EP3221360A1
(en)
|
2014-11-17 |
2017-09-27 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
JP6771464B2
(ja)
|
2014-11-27 |
2020-10-21 |
ジェネンテック， インコーポレイテッド |
Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
|
|
HK1243141A1
(zh)
|
2014-12-23 |
2018-07-06 |
豪夫迈．罗氏有限公司 |
用於治疗和诊断化学疗法抗性癌症的组合物和方法
|
|
JP2018503373A
(ja)
|
2014-12-30 |
2018-02-08 |
ジェネンテック， インコーポレイテッド |
がんの予後診断及び治療のための方法及び組成物
|
|
WO2016112251A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
|
JP6659703B2
(ja)
|
2015-01-09 |
2020-03-04 |
ジェネンテック， インコーポレイテッド |
ピリダジノン誘導体および癌の処置におけるそれらの使用
|
|
JP6855379B2
(ja)
|
2015-01-09 |
2021-04-07 |
ジェネンテック， インコーポレイテッド |
癌の処置のためのヒストンデメチラーゼｋｄｍ２ｂのインヒビターとしての（ピペリジン−３−イル）（ナフタレン−２−イル）メタノン誘導体および関連化合物
|
|
JP6709792B2
(ja)
|
2015-01-29 |
2020-06-17 |
ジェネンテック， インコーポレイテッド |
治療用化合物およびその使用
|
|
CN107438593B
(zh)
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
LT3263106T
(lt)
|
2015-02-25 |
2024-01-10 |
Eisai R&D Management Co., Ltd. |
Chinolino darinių kartumo sumažinimo būdas
|
|
CA2978226C
(en)
|
2015-03-04 |
2025-02-18 |
Eisai R&D Management Co., Ltd. |
COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
|
|
US10231973B2
(en)
|
2015-03-20 |
2019-03-19 |
Chai Tai Tianqing Pharmaceutical Group Co., Ltd. |
Salts of quinazoline derivative and method for preparing the same
|
|
KR20180002653A
(ko)
|
2015-04-07 |
2018-01-08 |
제넨테크, 인크. |
효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
|
|
RS61152B2
(sr)
|
2015-05-12 |
2024-06-28 |
Hoffmann La Roche |
Terapeutski i dijagnostički postupci za lečenje raka
|
|
HK1248773A1
(zh)
|
2015-05-29 |
2018-10-19 |
豪夫迈‧罗氏有限公司 |
用於癌症的治疗和诊断方法
|
|
JP2018518483A
(ja)
|
2015-06-08 |
2018-07-12 |
ジェネンテック， インコーポレイテッド |
抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
|
|
JP2018521019A
(ja)
|
2015-06-08 |
2018-08-02 |
ジェネンテック， インコーポレイテッド |
抗ｏｘ４０抗体を使用して癌を治療する方法
|
|
CN107801379B
(zh)
|
2015-06-16 |
2021-05-25 |
卫材R&D管理有限公司 |
抗癌剂
|
|
IL256080B2
(en)
|
2015-06-17 |
2025-06-01 |
Genentech Inc |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
|
RU2718048C2
(ru)
|
2015-08-20 |
2020-03-30 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое терапевтическое средство
|
|
JP6946270B2
(ja)
|
2015-08-26 |
2021-10-06 |
ファンダシオン デル セクトル プーブリコ エスタタル セントロ ナショナル デ インベスティゲーショネス オンコロジカス カルロス ３（エフ エス ピー クニオ） |
タンパク質キナーゼ阻害剤としての縮合三環化合物
|
|
KR20230125094A
(ko)
|
2015-09-25 |
2023-08-28 |
제넨테크, 인크. |
항-tigit 항체 및 이의 이용 방법
|
|
HRP20220227T1
(hr)
|
2015-12-16 |
2022-04-29 |
Genentech, Inc. |
Postupak priprave tricikličnih spojeva inhibitora p13k i postupci upotrebe navedenih spojeva u liječenju raka
|
|
ES2837428T3
(es)
|
2016-01-08 |
2021-06-30 |
Hoffmann La Roche |
Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
|
|
CN105732522A
(zh)
*
|
2016-02-01 |
2016-07-06 |
刘平 |
一种治疗牙周炎的药物组合物
|
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
|
CA3020718A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
JP7503887B2
(ja)
|
2016-04-15 |
2024-06-21 |
ジェネンテック， インコーポレイテッド |
がんを監視及び治療するための方法
|
|
WO2017180581A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2017205538A1
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Pyrazolopyridine derivatives for the treatment of cancer
|
|
WO2017205536A2
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
CN109312407A
(zh)
|
2016-06-08 |
2019-02-05 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック， インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
|
MX2019003934A
(es)
|
2016-10-06 |
2019-07-10 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｍｉｃ抗体及び使用方法
|
|
WO2018147275A1
(ja)
|
2017-02-08 |
2018-08-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
|
BR112019021411A2
(pt)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
|
|
RU2019134940A
(ru)
|
2017-05-16 |
2021-06-16 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Лечение гепатоцеллюлярной карциномы
|
|
IL271888B2
(en)
|
2017-07-21 |
2024-09-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
CN111295394B
(zh)
|
2017-08-11 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
抗cd8抗体及其用途
|
|
KR102811888B1
(ko)
|
2017-09-08 |
2025-05-27 |
에프. 호프만-라 로슈 아게 |
암의 진단 및 치료 방법
|
|
US11369608B2
(en)
|
2017-10-27 |
2022-06-28 |
University Of Virginia Patent Foundation |
Compounds and methods for regulating, limiting, or inhibiting AVIL expression
|
|
CA3077664A1
(en)
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
AU2019207535B2
(en)
|
2018-01-15 |
2021-12-23 |
Epiaxis Therapeutics Pty Ltd |
Agents and methods for predicting response to therapy
|
|
CA3092108A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
JP2021524744A
(ja)
|
2018-05-21 |
2021-09-16 |
ナノストリング テクノロジーズ，インコーポレイティド |
分子遺伝子シグネチャーとその使用方法
|
|
AU2019288728A1
(en)
|
2018-06-23 |
2021-01-14 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
TW202011991A
(zh)
|
2018-07-18 |
2020-04-01 |
美商建南德克公司 |
用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法
|
|
TW202024023A
(zh)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
CN112955747A
(zh)
|
2018-09-19 |
2021-06-11 |
豪夫迈·罗氏有限公司 |
膀胱癌的治疗和诊断方法
|
|
ES2955032T3
(es)
|
2018-09-21 |
2023-11-28 |
Hoffmann La Roche |
Métodos de diagnóstico para el cáncer de mama triple negativo
|
|
AU2019362972A1
(en)
|
2018-10-17 |
2021-05-20 |
The University Of Queensland |
Epigenetic biomarker and uses therefor
|
|
AU2019361983A1
(en)
|
2018-10-18 |
2021-05-20 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
EP3898626A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
JP2022515197A
(ja)
|
2018-12-19 |
2022-02-17 |
アレイ バイオファーマ インコーポレイテッド |
がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
|
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
CA3131268A1
(en)
|
2019-02-27 |
2020-09-03 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック， インコーポレイテッド |
抗ｔｉｇｉｔ抗体と抗ｃｄ２０抗体又は抗ｃｄ３８抗体とによる処置のための投薬
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
KR20220004744A
(ko)
|
2019-05-03 |
2022-01-11 |
제넨테크, 인크. |
항-pd-l1 항체를 이용하여 암을 치료하는 방법
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
EP4025608A1
(en)
|
2019-09-04 |
2022-07-13 |
F. Hoffmann-La Roche AG |
Cd8 binding agents and uses thereof
|
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
|
CN114728936A
(zh)
|
2019-10-29 |
2022-07-08 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的双功能化合物
|
|
US20220389103A1
(en)
|
2019-11-06 |
2022-12-08 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
|
WO2021097110A1
(en)
|
2019-11-13 |
2021-05-20 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
CN110963972A
(zh)
*
|
2019-11-21 |
2020-04-07 |
苏州明锐医药科技有限公司 |
一种喹唑啉衍生物及其制备方法与药物用途
|
|
KR20220113790A
(ko)
|
2019-12-13 |
2022-08-16 |
제넨테크, 인크. |
항-ly6g6d 항체 및 사용 방법
|
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2021154761A1
(en)
|
2020-01-27 |
2021-08-05 |
Genentech, Inc. |
Methods for treatment of cancer with an anti-tigit antagonist antibody
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
|
WO2021257124A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
WO2022031749A1
(en)
|
2020-08-03 |
2022-02-10 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
MX2023003338A
(es)
|
2020-09-23 |
2023-06-14 |
Erasca Inc |
Piridonas y pirimidonas tricíclicas.
|
|
JP2023544407A
(ja)
|
2020-10-05 |
2023-10-23 |
ジェネンテック， インコーポレイテッド |
抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2022171745A1
(en)
|
2021-02-12 |
2022-08-18 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
|
KR20240026948A
(ko)
|
2021-05-25 |
2024-02-29 |
에라스카, 아이엔씨. |
황 함유 헤테로방향족 트리사이클릭 kras 억제제
|
|
US20240293558A1
(en)
|
2021-06-16 |
2024-09-05 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
EP4384522A1
(en)
|
2021-08-10 |
2024-06-19 |
Erasca, Inc. |
Selective kras inhibitors
|
|
US12275745B2
(en)
|
2021-11-24 |
2025-04-15 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
JP2024541508A
(ja)
|
2021-11-24 |
2024-11-08 |
ジェネンテック， インコーポレイテッド |
治療用インダゾール化合物およびがんの治療における使用方法
|
|
CN114634453B
(zh)
*
|
2022-03-15 |
2023-10-10 |
沈阳工业大学 |
喹唑啉衍生物制备方法及其应用
|
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CA3251472A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
DOSAGE FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
|
|
KR20250022049A
(ko)
|
2022-06-07 |
2025-02-14 |
제넨테크, 인크. |
항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
|
|
CN119585308A
(zh)
|
2022-07-13 |
2025-03-07 |
基因泰克公司 |
针对用抗fcrh5/抗cd3双特异性抗体进行的治疗的给药
|
|
EP4558524A1
(en)
|
2022-07-19 |
2025-05-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
TW202417439A
(zh)
|
2022-08-11 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
雙環四氫噻吖呯衍生物
|
|
TW202417001A
(zh)
|
2022-08-11 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
雙環四氫吖呯衍生物
|
|
KR20250048020A
(ko)
|
2022-08-11 |
2025-04-07 |
에프. 호프만-라 로슈 아게 |
바이시클릭 테트라히드로티아제핀 유도체
|
|
MA71727A
(fr)
|
2022-08-11 |
2025-05-30 |
F. Hoffmann-La Roche Ag |
Dérivés bicycliques de tétrahydrothiazépine
|
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
WO2024173842A1
(en)
|
2023-02-17 |
2024-08-22 |
Erasca, Inc. |
Kras inhibitors
|
|
AU2024270495A1
(en)
|
2023-05-05 |
2025-10-09 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024254455A1
(en)
|
2023-06-08 |
2024-12-12 |
Genentech, Inc. |
Macrophage signatures for diagnostic and therapeutic methods for lymphoma
|
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2025049277A1
(en)
|
2023-08-25 |
2025-03-06 |
Genentech, Inc. |
Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
|